Cover Image
市場調查報告書

急性冠狀動脈症候群 (ACS) 的全球市場:2015-2019年

Global Acute Coronary Syndrome (ACS) Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 326301
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
急性冠狀動脈症候群 (ACS) 的全球市場:2015-2019年 Global Acute Coronary Syndrome (ACS) Market 2015-2019
出版日期: 2015年03月18日 內容資訊: 英文 97 Pages
簡介

全球急性冠狀動脈症候群 (ACS) 的市場預計從2014年到2019年以13.24%的年複合成長率成長。

本報告提供全球急性冠狀動脈症候群 (ACS) 的市場相關調查,急性冠狀動脈症候群 (ACS) 概要,分類,診斷法,管理法,主要藥物開發平台狀況,市場規模的變化與預測,各地區的趨勢,市場成長的各種影響因素分析,競爭環境與主要企業的市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 關於疾病
  • 病患的負擔
  • 病因
  • 病理生理
    • 心肌功能不全
    • 心肌梗塞
    • 電力的功能不全
  • 預後
  • 流行病學
    • 冠狀動脈疾病的盛行率
  • 診斷
    • 心電圖 (ECG)
    • 血液檢驗
    • 核醫學診斷
    • CT
  • 管理

第7章 ACS開發平台環境

  • 主要的開發平台分子

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 各ECG輸出市場

第10章 各地區市場

第11章 購買標準

第12章 推動市場成長要素

第13章 成長推動因素與其影響

第14章 市場課題

第15章 成長推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Sanofi
  • 其他卓越供應商

第19章 主要供應商分析

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Sanofi
    • 主要資料
    • 產業概要
    • 產業區分
    • 各產業分類收益
    • 各地區收益
    • 產業策略
    • 主要的發展趨勢
    • SWOT分析等

第20章 相關報告

圖表

目錄
Product Code: IRTNTR5471

About ACS

ACS is a condition that results in sudden and reduced blood flow to the heart. ACS is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and short-term mortality. On the basis of evidence of heart muscle damage and changes in the ST-tracing of the ECG, ACS is classified into three categories: STEMI, NSTEMI, and UA. ACS is treatable if it is diagnosed quickly. The treatment options for ACS vary, depending on the signs, symptoms, and overall health condition.

TechNavio's analysts forecast the Global ACS market to grow at a CAGR of 13.24 percent over the period 2014-2019.

Covered in this Report

The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA. This report covers the present scenario and the growth prospects of the Global ACS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of ACS.

TechNavio's report, the Global ACS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global ACS market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Astra Zeneca
  • BMS
  • Eli Lilly
  • GSK
  • Sanofi

Other Prominent Vendors

  • AbbVie
  • Amgen
  • Bayer
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Portola Pharmaceuticals
  • Teva Pharmaceutical

Market Driver

  • Increase in Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expirations
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Burden of Disease
  • 06.3. Etiology
  • 06.4. Pathophysiology
    • 06.4.1. Myocardial Dysfunction
    • 06.4.2. MI
    • 06.4.3. Electrical Dysfunction
  • 06.5. Prognosis
  • 06.6. Epidemiology
    • 06.6.1. Prevalence of Coronary Artery Disease
  • 06.7. Diagnosis
    • 06.7.1. ECG
    • 06.7.2. Blood Tests
    • 06.7.3. Nuclear Scan
    • 06.7.4. CT
  • 06.8. Management

07. ACS Pipeline Landscape

  • 07.1. Key Pipeline Molecules

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by ECG Output

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. AstraZeneca
    • 18.2.2. Bristol-Myers Squibb
    • 18.2.3. Eli Lilly
    • 18.2.4. GlaxoSmithKline
    • 18.2.5. Sanofi
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. AstraZeneca
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Business Segmentation by Revenue 2011-2013
    • 19.1.5. Revenue by Geography
    • 19.1.6. Business Strategy
    • 19.1.7. Key Developments
    • 19.1.8. SWOT Analysis
  • 19.2. Bristol-Myers Squibb
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Key Product Offerings
    • 19.2.4. Revenue by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Eli Lilly
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue
    • 19.3.4. Revenue by Geography
    • 19.3.5. Business Strategy
    • 19.3.6. Key Information
    • 19.3.7. SWOT Analysis
  • 19.4. GlaxoSmithKline
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Revenue by Geography
    • 19.4.6. Pipeline Products
    • 19.4.7. Business Strategy
    • 19.4.8. Key Information
    • 19.4.9. SWOT Analysis
  • 19.5. Sanofi
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue by Business Segmentation
    • 19.5.5. Revenue Comparison 2012 and 2013
    • 19.5.6. Revenue by Geography
    • 19.5.7. Business Strategy
    • 19.5.8. Key Developments
    • 19.5.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Spectrum of ACS
  • Exhibit 3: Overview of ACS
  • Exhibit 4: Pathogenesis of ACS
  • Exhibit 5: Hospitalized Incident Cases of ACS 2014-2019 (millions)
  • Exhibit 6: Epidemiologic Transition of CV Diseases
  • Exhibit 7: Initial Drug Therapy for ACS
  • Exhibit 8: Adjunctive Drug Therapy for ACS
  • Exhibit 9: Surgery and Other Procedures
  • Exhibit 10: Snapshot of Global ACS Market 2014
  • Exhibit 11: Global ACS Market 2014-2019 (US$ billion)
  • Exhibit 12: Global ACS Market Share of Branded and Generic Drugs 2014 and 2019 (in Percent)
  • Exhibit 13: Segmentation of Global ACS Market by ECG Output
  • Exhibit 14: Diagrammatic Representation of STEMI, NSTEMI, and UA
  • Exhibit 15: Segmentation of Global ACS Market by ECG Output 2014
  • Exhibit 16: Global ACS Market by Geography 2014
  • Exhibit 17: Drivers of Global ACS Market
  • Exhibit 18: Comparison of Elderly Population 2012 and 2050 (Aged 65 and Older)
  • Exhibit 19: Challenges in Global ACS Market
  • Exhibit 20: Trends in Global ACS Market
  • Exhibit 21: Global Revenue of AstraZeneca for CV and Metabolic Diseases 2011-2013 (US$ million)
  • Exhibit 22: Estimated Filings of Brilinta/Brilique
  • Exhibit 23: Line Extensions for Brilinta/Brilique
  • Exhibit 24: Global Revenue of Brilinta/Brilique by AstraZeneca 2011-2013 (US$ million)
  • Exhibit 25: Global Revenue of Plavix by Bristol-Myers Squibb 2010-2012 (US$ million)
  • Exhibit 26: Revenue of Eli Lilly by Therapeutic Area 2013
  • Exhibit 27: Global Revenue of Effient by Eli Lilly 2010-2013 (US$ million)
  • Exhibit 28: Global Revenue of Arixtra by GlaxoSmithKline 2011-2013 (US$ million)
  • Exhibit 29: Global Revenue of Plavix by Sanofi 2011-2013 (US$ million)
  • Exhibit 30: Global Revenue of Lovenox by Sanofi 2011-2013 (US$ million)
  • Exhibit 31: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 32: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 33: AstraZeneca: Revenue by Geography 2013
  • Exhibit 34: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 35: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 37: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 38: Eli Lilly: Revenue by Geography 2013
  • Exhibit 39: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 40: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 41: GlaxoSmithKline: Revenue by Geography 2013
  • Exhibit 42: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 43: Sanofi: Business Segmentation
  • Exhibit 44: Sanofi: Revenue by Business Segmentation 2013
  • Exhibit 45: Sanofi: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 46: Sanofi: Revenue by Geographical Segmentation 2013
Back to Top